Anti-Japanese Encephalitis Virus (Clone: JEV-69)

Reactivity Species : Japanese Encephalitis-Virus Expression Host : HEK-293 Endotoxin Level :≤ 1.0 EU/mg as determined by the LAL method Specificity : Clone JEV-69 activity is directed against DIII-LR of the E protein. JEV-69 has no cross-reactivity to West Nile Virus or Zika Virus E proteins. Background : Japanese Encephalitis Virus (JEV) is a mosquito-borne, enveloped positive-stranded RNA virus in the Flavivirus genus endemic to Asia and parts of the western Pacific1. Symptomatic JEV infection is most common in children in areas of endemicity or travelers to those regions. Severe symptoms occur in ~1% of cases, with a case-fatality ratio of 2030%. Survivors often have neurologic, cognitive, or psychiatric sequelae issues. Five JEV genotypes have been identified, and existing vaccines are derived from historically predominant GIII strains2.

Product Specifications

Product Name Alternative

JEV

Host

Human

Immunogen

A panel of human mAbs against JEV, including JEV-69, was generated from donors immunized with a GIII vaccine strain (JEV-SA14-14-2) .

Clonality

Monoclonal

Clone

JEV-69

Applications

ELISA

Purification

>=95% monomer by analytical SEC

Components

>= 5.0 mg/mL Formulation : This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added

Storage Conditions

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at >= -70°C. Avoid Repeated Freeze Thaw Cycles.